Clal Biotechnology Fundamental Relationships

CBI -- Israel Stock  

ILS 314.20  0.60  0.19%

The Drivers Module shows relationships between Clal Biotechnology's most relevant fundamental drivers and provides multiple suggestions of what could possibly affect the performance of Clal Biotechnology Industries Ltd over time as well as its relative position and ranking within its peers. Check also Trending Equities

Clal Biotechnology Price to Book vs. Current Ratio Fundamental Analysis

Clal Biotechnology Industries Ltd is rated below average in current ratio category among related companies. It is rated fourth in price to book category among related companies fabricating about  41.92  of Price to Book per Current Ratio.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Clal Biotechnology 
Current Ratio 
Current Asset 
Current Liabilities 
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e. Current Ration of 2 to 1).
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is accounting value of assets minus liabilities.
Clal Biotechnology 
MV Per Share 
BV Per Share 
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Clal Biotechnology Price to Book Comparison

Clal Biotechnology is rated third in price to book category among related companies.
      Chicago Bridge Comparables 
Clal Biotechnology is the top company in revenue category among related companies.